

# **AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA325)**

## **NICE GUIDANCE ISSUED NOVEMBER 2014**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

### **Final Appraisal Recommendation**

**Advice No: 0414 – January 2014**

### **Nalmefene (Selincro<sup>®</sup>▼) 18 mg film-coated tablets**

#### **Submission by Lundbeck Ltd**

#### **Recommendation of AWMSG**

**Nalmefene (Selincro<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL) without physical withdrawal symptoms and who do not require immediate detoxification.**

**Nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.**

**Nalmefene should be initiated only in patients who continue to have a high DRL two weeks after initial assessment.**

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1259), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Marketing authorisation holder on first issue:	Lundbeck Ltd
Date of first issue	January 2014
Last reviewed	February 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0414:  
Nalmefene (Selincro<sup>®</sup>) 18 mg film-coated tablets. January 2014.